Brand Loss of Exclusivity (LOE)
A large pharmaceutical brand that had experienced years of patent exclusivity recently entered a point in its lifecycle where generic entrants were knocking on its door. The brand was predicted to face generic competition from several competitors over the next six months for the first time since its approval. The brands’ finance and commercial teams were in a challenging position of planning for the Loss of Exclusivity (LOE). The teams faced an onslaught of new questions not addressed in the brand’s past promotional and growth phases. What is my current and future inventory exposure? What are my expected returns at LOE? What are the proper accruals levels to account for during LOE? During an LOE event, how will the revenue recognition model be impacted? How do I address these questions in a manner that I can justify it to my external auditors?
ValueCentric was asked to provide data, modeling, and consultative support to address the commercial and finance teams’ key concerns and address business questions around the loss of exclusivity (LOE). ValueCentric’s approach provided the knowledge to estimate exposure of downstream inventories, estimate return rates (for example, 180), specify accrual rates on rebates, and determine promotional liabilities. Backed by ValueCentric’s industry insight and accounting expertise, we employed our proprietary methodology for projecting the timing and quantity of future returns giving the audit teams the transparency and level of detail needed to support accrual assumptions.
The solutions provided both to the brand and finance commercial teams resulted in one view of the inventory and return estimates during the period of LOE. with ValueCentric’s highly effective methodology for projecting the timing and quantities for future returns, audit teams were provided with the detail and transparency needed to support accrual assumptions. the results provided tighter and more reliable gross to net estimates for the brand during the start of generic competition. ValueCentric saved the client tens of millions of dollars in inventory and manufacturing costs by identifying channel-specific inventories and informing the manufacturer how to repurpose inventory, given the drastic changes in demand.
ValueCentric is the leading data aggregation, analytics, and reporting platform for healthcare manufacturers and their delivery partners. Its innovative technologies cleanse, normalize, and integrate data to provide a complete picture of the product and patient journey for a variety of manufacturers, including Specialty, Branded, Generic, and Medical Products companies. Their cloud-based platform, ValueTrak, enables dynamic data sharing to achieve operational efficiencies, improve market access, and optimize the ability to serve patient needs.